Jazz Venture Partners

Founded 2015
Founders Adam Gazzaley Andrew Firlik John Harris John Spinale Zack Lynch

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 44
Average round size
info
The average size of a deal this fund participated in
$29M
Portfolio companies 29
Rounds per year 7.33
Lead investments 10
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Exits 5
Key employees 8

Areas of investment

  • Health Care
  • Therapeutics
  • Software
  • Artificial Intelligence
  • Medical
Summary

Jazz Venture Partners appeared to be the VC, which was created in 2015. The venture was found in North America in United States. The main department of described VC is located in the San Francisco.

Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Pear Therapeutics, Akili Interactive Labs, Augment CXM. Among the most successful fund investment fields, there are Consumer Electronics, Artificial Intelligence. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

The current fund was established by Adam Gazzaley, Andrew Firlik, John Harris, John Spinale, Zack Lynch. We also calculated 10 valuable employees in our database.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Jazz Venture Partners, startups are often financed by Intel Capital, Randstad Innovation Fund, Lux Capital. The meaningful sponsors for the fund in investment in the same round are Intel Capital, Arboretum Ventures, Temasek Holdings. In the next rounds fund is usually obtained by Temasek Holdings, Novartis, M Ventures.

The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2016. Speaking about the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The average startup value when the investment from Jazz Venture Partners is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year. This Jazz Venture Partners works on 24 percentage points less the average amount of lead investments comparing to the other organizations.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

AllStripes

Health Care
Medical
$50M24 Aug 2021 San Francisco, California, United States

Mahana Therapeutics

Information Technology
Internet
Medical
Therapeutics
$61M11 Aug 2021 San Francisco, California, United States

Woebot Health

Artificial Intelligence
Health Care
Therapeutics
$90M21 Jul 2021 San Francisco, California, United States

Zeitworks

Enterprise Software
Machine Learning
SaaS
Software
$2M07 Jul 2021 Seattle, Washington, United States

Akili Interactive Labs

Biotechnology
Health Care
Medical
Medical Device
Neuroscience
Therapeutics
$110M26 May 2021 Boston, Massachusetts, United States

ŌURA

Health Care
Mobile Apps
Wearables
Wellness
$100M04 May 2021 Oulu, Oulu, Finland

Blue Note Therapeutics

Health Care
Health Diagnostics
Medical
Therapeutics
$26M03 Mar 2021 San Francisco, California, United States

Outside

Advertising
Information Services
Publishing
Social Media
$150M22 Feb 2021 Boulder, Colorado, United States

RxRevu

Analytics
Health Care
Hospital
Information Technology
$7M27 Jan 2021 Denver, Colorado, United States
News
Magnus Medical Raises $25M in Series A Financing

– Magnus Medical, Inc. from Burlingame is developing non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments.
– The company raised $25m in Series A funding.
– The round was co-led by Jazz Venture Partners and Red Tree Venture Capital.

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

– Blue Note Therapeutics raised an additional $5.2m in Series A financing, bringing the company’s Series A financing to a total of $31m.
– The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.
– The additional proceeds will strengthen Blue Note’s capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Jazz Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: